Regeneron Pharmaceuticals Inc(REGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | NDX, S&P 500 | P/E | 19.9 | EPS (ttm) | 40.46 | Insider Own | 3.78% | Shs Outstand | 101.6M | Perf Week | 1.81% |
| Market Cap | 82.88B | Forward P/E | 12.69 | EPS next Y | 5.93% | Insider Trans | -0.22% | Shs Float | 99.1M | Perf Month | 1.13% |
| Enterprise Value | 77.58B | PEG | 0.77 | EPS next Q | 16.36 | Inst Own | 91.51% | Short Float | 2.17% | Perf Quarter | 20.66% |
| Income | 4.33B | P/S | 5.34 | EPS this Y | 35.14% | Inst Trans | -0.39% | Short Ratio | 2.9 | Perf Half Y | 7.11% |
| Sales | 15.53B | P/B | 2.62 | EPS next 5Y | 16.39% | ROA | 10.83% | Short Interest | 2.15M | Perf YTD | 4.29% |
| Book/sh | 306.69 | P/C | 10.35 | EPS past 3/5Y | 2.76% 6.33% | ROE | 14.04% | 52W High | -6.32% ($859.34) | Perf Year | 39.84% |
| Cash/sh | 77.75 | P/FCF | 22.04 | Sales past 3/5Y | 5.62% 11.04% | ROIC | 12.85% | 52W Low | 40.55% ($572.75) | Perf 3Y | 1.19% |
| Dividend Est. | $3.54 (0.44%) | EV/EBITDA | 16.5 | EPS Y/Y TTM | 0.38% | Gross Margin | 81.46% | Volatility(W/M) | 2.38% 2.75% | Perf 5Y | 40.65% |
| Dividend TTM | 3.7 | EV/Sales | 4.99 | Sales Y/Y TTM | 9.29% | Oper. Margin | 26.87% | ATR (14) | 21.32 | Perf 10Y | 121.45% |
| Dividend Ex-Date | 2026/8/18 | Quick Ratio | 2.78 | EPS Q/Q | -4.52% | Profit Margin | 27.86% | RSI (14) | 58.04 | Recom | 1.87 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.34 | Sales Q/Q | 16.73% | SMA20 | 5.06% ($766.25) | Beta | 0.13 | Target Price | $872.62 |
| Payout | 8.49% | Debt/Eq | 0.09 | Earnings | 2026/10/30 | SMA50 | 1.72% ($791.41) | Rel Volume | 0.71 | Prev Close | $819.09 |
| Employees | 15410 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 40.69% 12.4% | SMA200 | 9.38% ($735.98) | Avg Volume(3M) | 0.74M | Price | $805.02 |
| IPO | 1991/4/2 | Option/Short | Yes/Yes | Trades | 15572 | Volume | 527,741 | Change | -1.72% |
🧬 Regeneron Pharmaceuticals (REGN) is a major US biotech company that has developed innovative new drugs across a broad range of areas—including ophthalmology, immunology, oncology, cardiovascular, and rare diseases—based on its proprietary antibody discovery platform. The company has a stable revenue foundation built around two main pillars: Eylea and its high-dose Eylea formulation for the treatment of macular degeneration, and Dupixent, the immunology blockbuster co-commercialized with Sanofi.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded less than usual. That is 71% of its average volume.
Next earnings report: October 30
4 days to go.
REGN makes money exceptionally well
Of every $100 in sales, $26.87 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +35.1% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $1,269. Peers typically go for $2,305. Compared with its own 5-year average, it is 11% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +40.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.44% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 91.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #2 of 595 in the industry
Based on market cap of $83B.
VRTX#1 Vertex Pharmaceuticals Inc $133B PER 30.5 
REGN#2 Regeneron Pharmaceuticals Inc $83B PER 19.9 
MRNA#3 Moderna Inc $80B PER - 
ARGX#4 Argen X SE ADR $55B PER 33.3 
RVMD#5 Revolution Medicines Inc $40B PER - 
FAQ
What kind of company is REGN?
REGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of REGN?
The market cap of REGN is approximately $82.9B, ranking 202 within its sector.
Does REGN pay dividends?
REGN has a dividend yield of approximately 0.44%, with an annual dividend of $3.54.
What is the P/E ratio of REGN?
REGN has a P/E ratio of approximately 19.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for REGN?
REGN has recorded a 52-week high of $859.34 and a low of $572.75.
